Work

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Year: 2013

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-12-3529

Authors: Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei, Diane P. Leffingwell, S. Gail Eckhardt, Lia Gore, Karl D. Lewis, Glen J. Weiss, Ramesh K. Ramanathan, Grace K. Dy, Wen W. Ma, Beth Sheedy, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li-Tain Yeh, Ronald L. Dubowy, Michael Jeffers, Prabhu Rajagopalan, Neil J. Clendeninn

Institutions: Translational Genomics Research Institute, Roswell Park Comprehensive Cancer Center, Bayer (United States), University of Colorado Cancer Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Bayer HealthCare

OpenAlex ID: W2080931115

FWCI: 4.476

Cites: 33

Cited by: 59

Related to: 10